Kyowa Hakko Kirin

Kyowa Hakko Kirin, a company incorporated in 2008, has its headquarters in Chiyoda, Tokyo, Japan. It operates primarily in two business segments: Pharmaceuticals and Bio-chemicals. The pharmaceutical segment focuses on a range of therapeutic categories such as oncology, nephrology, central nervous system, and immunology. The bio-chemicals segment is known for providing amino acids, nucleic acids, and fine chemicals for various applications. Notable products from Kyowa Hakko Kirin include Poteligeo (mogamulizumab) for cancer immunotherapy, Nesp (darbepoetin alfa), which is also marketed as Aranesp in some locations for treating anemia, Crysvita (burosumab) for X-linked hypophosphatemia, and G-Lasta (romiplostim) for chronic immune thrombocytopenia. The company's product portfolio is subject to change as pharmaceutical developments progress and market demands shift. Kyowa Hakko Kirin has a global presence, with key markets being its home country Japan, as well as the United States, Europe, and various countries across Asia. The significance of each market may differ depending on the product in question and the specific time period. (Powered by AI)